TABLE 3

Effect of bevacizumab, oxaliplatin, and the combination therapy of bevacizumab and oxaliplatin on the growth delay of HTpc3-, HTM9-, and HTS13-derived tumors

Tumor growth delay was calculated as time (days) needed for treated tumor to grow from 100 to 600 mm3 minus the time needed for control tumor to grow to the same size. P values are treated versus untreated tumors.

Treatment
Tumor Growth Delay
HTpc3a
 HTM9b
P
 HTS13b
P
Bevacizumab 5.4 2.7 <0.01 8 <0.01
Oxaliplatin 7.5 2 <0.001 10 <0.01
Bevacizumab + Oxaliplatin
10.9
1.4
<0.001
13
<0.05

  • ↵ a Mean values from the 12 tumors.

  • ↵ b Mean values from the six tumors.